CHEMRNA
Live / Applied — First extension granted (statement of use) (as of 10 Sept 2026)
What this means for you
Not registered yet, but its 14 Jan 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98960020
- Mark type
- Stylized text
- Filed
- 14 Jan 2025
- Published for opposition
- 28 Apr 2026
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 001 — Chemicals: Assays and reagents for use in scientific and biomedical research
- Class 005 — Pharmaceuticals: pharmaceutical preparations, vaccines and medical therapeutics for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations, vaccines and medical therapeutics for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; vaccines for human use; nutritional and dietary supplements for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; pharmaceutical preparations, vaccines and medical therapeutics for the prevention and treatment of blood disorders, bone disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes
- Class 042 — Scientific and technological services: research and development of therapeutic antibodies and pharmaceuticals, and research and development of technology in the field of therapeutic antibodies, pharmaceuticals and biopharmaceuticals; development of pharmaceutical preparations, vaccines and medicines; clinical studies; drug development and discovery; medical research for development of therapeutic modalities for treatment of diseases; research and development of pharmaceutical preparations, vaccines and therapeutic drugs for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; research and development of therapeutic modalities for treatment of aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; preclinical and clinical development of therapeutic products
Owner
- Convergence Bio, Inc., Boston, MA, US
- Convergence Bio, Inc., Boston, MA, US
Prosecution history
- 11 Sept 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Sept 2026 — SOU EXTENSION 1 GRANTED
- 10 Sept 2026 — SOU EXTENSION 1 FILED
- 10 Sept 2026 — SOU TEAS EXTENSION RECEIVED
- 23 Jun 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 28 Apr 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 28 Apr 2026 — PUBLISHED FOR OPPOSITION
- 22 Apr 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 31 Mar 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 31 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 31 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 31 Mar 2026 — ASSIGNED TO LIE
- 27 Mar 2026 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
- 30 Oct 2025 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 30 Oct 2025 — LETTER OF SUSPENSION E-MAILED